GLIMEFON M1 combines Glimepiride, a sulfonylurea that promotes insulin secretion, with
Metformin, a biguanide that improves insulin sensitivity and reduces hepatic glucose production.
This synergistic combination ensures comprehensive management of type 2 diabetes mellitus,
especially in patients inadequately controlled by monotherapy.
Key Benefits:
● Dual mechanism: enhances insulin release & reduces insulin resistance
● Provides better HbA1c control and postprandial glucose reduction
● Helps delay diabetes progression and prevent complications
● Improves pancreatic β-cell function
● Well-tolerated with a low risk of hypoglycemia (when used appropriately)
Indications:
● Type 2 Diabetes Mellitus (when diet, exercise, and monotherapy are not enough)
● Suitable for newly diagnosed patients or those needing combination therapy
● Reduces the risk of diabetes-related cardiovascular and renal complications